To view this email as a web page, click here.

ONCOLOGY: Practical, Peer-Reviewed Perspectives

Volume 33, Number 8

Click here to view the full table of contents

Click here for the Digital Edition

CLINICAL QUANDRIES

What Are Treatment Options After Progression in PDL-1–Positive Metastatic Lung Adenocarcinoma after Chemo/IO?

Yuly A. Remolina-Bonilla, MD, Raul R. Trejo-Rosales, MD, Bruno Saldivar-Oviedo, Alejandro Gabutti, MD, and Maria T. Bourlon MD, MS
What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

INTERVIEW

Pediatric Acute Lymphoblastic Leukemia

Susan R. Rheingold, MD
ONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children's Hospital of Philadelphia.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.